This drug has the potential to be more targeted than others currently being studied, and we hope it will result in fewer ...

A peptide inhibitor called RI-AG03 targets major aggregation “hot spots” of tau proteins, believed to be a key driver of ...

The drug is RI-AG03, and it's a peptide inhibitor (a blocker of proteins). In tests on fruit flies and human cells, it has ...

“This research is taking promising steps towards a new one-of-a-kind therapy which targets tau, a damaging protein in the ...

Further research could also help explain and even predict variation in the onset of behavioral changes in people with ...

Researchers have discovered that disruptions in the brain’s salience network, often tied to tau protein buildup, correlate strongly with behavioral changes in people with early-stage dementia.

Scientists have developed a drug that targets both major aggregation-promoting sites of the Tau protein, a key player in ...

AG03, developed by researchers at the University of Southampton, targets two critical regions of the tau protein linked to ...

An international team of researchers has made a significant breakthrough in Alzheimer's drug development with the ...

AG03, targets two key areas of the Tau protein in Alzheimer's disease, showing effectiveness in lab and fruit fly models.

DEPTAC. Based on PROTACs, or protein-targeting chimeras, D20, a dephosphorylation-targeting chimera, delivers PP1 to tau. The C-terminal tail (gray) helps the construct enter cells. [Courtesy of Xiao ...